bioMerieux (OTCMKTS:BMXMF) Reaches New 1-Year Low – What’s Next?

bioMerieux (OTCMKTS:BMXMF)’s share price hit a new 52-week low during trading on Friday . The stock traded as low as $77.32 and last traded at $77.32, with a volume of 15 shares. The stock had previously closed at $84.21.

Wall Street Analyst Weigh In

Several analysts have recently commented on the company. UBS Group downgraded bioMerieux from a “buy” rating to a “neutral” rating in a research note on Monday, June 1st. Zacks Research raised bioMerieux to a “hold” rating in a research note on Tuesday, April 28th. Deutsche Bank Aktiengesellschaft downgraded bioMerieux from a “buy” rating to a “hold” rating in a research note on Friday, April 24th. Finally, Piper Sandler assumed coverage on bioMerieux in a research note on Thursday. They issued a “neutral” rating for the company. Five investment analysts have rated the stock with a Hold rating, Based on data from MarketBeat, the stock has an average rating of “Hold”.

bioMerieux Price Performance

The firm has a 50 day moving average price of $91.37 and a 200 day moving average price of $109.65. The company has a quick ratio of 1.48, a current ratio of 2.39 and a debt-to-equity ratio of 0.08.

bioMerieux Company Profile

bioMérieux is a global leader in in vitro diagnostics, specializing in the development, manufacture and distribution of diagnostic solutions that determine the source of disease and contamination to improve patient health and ensure consumer safety. The company’s product portfolio encompasses a broad range of assays and instruments for microbiological and immunoassay testing, including molecular diagnostics for infectious diseases, immunoassays for autoimmune and oncology markers, and traditional microbial identification and antimicrobial susceptibility testing.